Trulieve Cannabis (TRLV): Is the $15 Level in Sight?
Key Takeaways
- The central question is whether Trulieve Cannabis Corp. (TRLV) can climb to a $15 price target, the lowest point of the current analyst range and a round-number milestone above its 52-week high.
- The strongest bullish factors include Trulieve's status as the first U.S. cannabis company listed on the New York Stock Exchange, strong cash generation, and federal rescheduling of medical marijuana to Schedule III.
- The biggest risks are ongoing regulatory uncertainty, a net-loss bottom line, and a volatile share price that has swung sharply within a wide 52-week range.
- The resistance level at the 52-week high near $13.28 must be cleared before $15 becomes realistic, while recent support has formed in the roughly $9–10 area.
- Analysts remain broadly constructive, with a consensus average target of about $18, but reaching $15 still requires roughly 35%–40% upside from recent prices.
- Investors should weigh the favorable sentiment against execution and regulatory risks rather than treating $15 as an assured outcome.
Why $15 Is the Level Investors Are Watching
Trulieve Cannabis Corp. has quickly become one of the most closely followed names in the U.S. cannabis sector after making history in mid-2026 as the first domestic marijuana company to list on the New York Stock Exchange. That uplisting, which followed the federal rescheduling of medical cannabis to Schedule III, drew a wave of fresh analyst coverage. Notably, Cantor Fitzgerald initiated coverage with an Overweight rating and a $15 price target, and $15 also represents the low end of the broader analyst range, which spans roughly $15 to $21. For investors searching for a realistic near-term objective, $15 sits just above the stock's 52-week high and stands out as a natural psychological milestone.
Company Overview and Current Market Position
Trulieve is a Florida-based, vertically integrated medical cannabis operator that cultivates, processes, and sells its products through its own dispensaries and home delivery. It operates across states including Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania. The company generated about $1.18 billion in revenue in 2025 and reported second-quarter 2026 revenue of roughly $271 million, with adjusted earnings per share (EPS) of $0.11 that beat consensus estimates of $0.03.
Fundamentals remain mixed. Trulieve delivered a 60% gross margin and reported operating cash flow of approximately $109 million and free cash flow of about $74 million in the first half of 2026, but it still posts a net loss and carries no dividend. The shares, with a market capitalization near $2.1 billion, have traded in a wide 52-week range of approximately $4.62 to $13.28, reflecting the sector's elevated volatility.
What Could Drive the Next Leg Higher
Several catalysts support the case for a move toward $15. The NYSE listing meaningfully expanded Trulieve's institutional investor base and improved its access to capital, a step that historically accompanies higher valuations. The Schedule III rescheduling removes a major overhang for U.S. cannabis operators by easing certain tax and banking constraints. Trulieve's continued expansion, including the launch of Georgia's expanded medical program, provides a growth runway, while a recently announced share repurchase program signals management confidence in the company's value. Positive free cash flow also distinguishes Trulieve from many peers that continue to burn cash. From what I see, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Could Prevent the Move
The path to $15 is not without obstacles. Despite improving operations, Trulieve remains unprofitable on a net-income basis, and the company's financial forecasts suggest revenue may decline modestly in the near term. The broader cannabis industry still faces fragmented state-level regulation and uncertainty over the pace of further federal reform. The stock's high beta and wide trading range mean sharp drawdowns can occur quickly, and any setback in Florida's market dynamics—Trulieve's most important state—could pressure sentiment. Clearing the prior high near $13.28 will require sustained buying interest and continued execution.
Analyst Opinions and Price Targets
Wall Street's view is decidedly optimistic. According to data aggregators, analysts polled by S&P Global rate Trulieve a consensus Strong Buy, with an average 12-month price target of roughly $18.18. Individual targets range from $15 (Cantor Fitzgerald) to $21, with firms such as Alliance Global Partners and Canaccord Genuity carrying $20 targets and Roth MKM at $19. This means the $15 milestone sits comfortably below the consensus forecast, suggesting most analysts see it as an achievable interim level rather than a stretch goal.
Technical Levels That Matter
From a technical perspective, the 52-week high near $13.28 is the first major resistance level that must be overcome before $15 enters play. Because $15 is also a round, psychologically significant number that sits above all recent trading, it is likely to attract selling pressure from investors looking to lock in gains. On the downside, the $9–10 zone has served as recent support, with the 52-week low near $4.62 marking the extreme risk level. The stock's overall trend remains constructive after its uplisting-driven rally, but the distance between current prices and $15 still requires roughly one-third to two-fifths of additional upside. I’m watching this closely as the resistance test unfolds.
Final Assessment
Trulieve reaching $15 is a plausible but not guaranteed outcome. The strongest supporting factors—the historic NYSE listing, Schedule III rescheduling, positive free cash flow, and a consensus analyst target well above $15—suggest the stock has a credible foundation for further gains. However, the primary risks, including persistent net losses, regulatory uncertainty, and the need to clear the $13.28 prior high, cannot be ignored. Investors should monitor quarterly execution, cash-flow trends, and any developments in federal cannabis policy as the key signals for whether the $15 price target becomes achievable in the months ahead.
Using Tickeron AI Daily Buy/Sell Signals
For traders monitoring whether Trulieve can sustain momentum toward higher levels, I rely on Tickeron’s AI Daily Buy/Sell Signals as a data-driven way to track shifting conditions. The product uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. In my view, these signals help me discover new opportunities, monitor existing positions, and identify changing market trends more efficiently than manual screening alone.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TRLV in upward trend: 10-day moving average broke above 50-day moving average on August 19, 2026
The 10-day moving average for TRLV crossed bullishly above the 50-day moving average on August 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on TRLV as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for TRLV just turned positive on August 03, 2026. Looking at past instances where TRLV's MACD turned positive, the stock continued to rise in of 36 cases over the following month. The odds of a continued upward trend are .
TRLV moved above its 50-day moving average on August 13, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TRLV advanced for three days, in of 235 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 142 cases where TRLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 21 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
TRLV broke above its upper Bollinger Band on August 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TRLV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.039) is normal, around the industry mean (47.010). P/E Ratio (0.000) is within average values for comparable stocks, (93.888). TRLV's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.974). TRLV has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.028). P/S Ratio (2.042) is also within normal values, averaging (177.089).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement